Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 18;10(1):33.
doi: 10.1038/s41597-023-01928-3.

Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation

Affiliations

Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation

Ahmed W Moawad et al. Sci Data. .

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver neoplasm, and its incidence has doubled over the past two decades owing to increasing risk factors. Despite surveillance, most HCC cases are diagnosed at advanced stages and can only be treated using transarterial chemo-embolization (TACE) or systemic therapy. TACE failure may occur with incidence reaching up to 60% of cases, leaving patients with a financial and emotional burden. Radiomics has emerged as a new tool capable of predicting tumor response to TACE from pre-procedural computed tomography (CT) studies. This data report defines the HCC-TACE data collection of confirmed HCC patients who underwent TACE and have pre- and post-procedure CT imaging studies and available treatment outcomes (time-to-progression and overall survival). Clinically curated segmentation of pre-procedural CT studies was done for the purpose of algorithm training for prediction and automatic liver tumor segmentation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
A schematic overview of the process of the dataset curation and processing in TCIA.

References

    1. Armstrong SA, He AR. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future. Clinics in Liver Disease. 2020;24:739–753. doi: 10.1016/j.cld.2020.07.007. - DOI - PubMed
    1. Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepatic Oncology. 2020;7:HEP27. doi: 10.2217/hep-2020-0024. - DOI - PMC - PubMed
    1. Kim H-s, El-Serag HB. The Epidemiology of Hepatocellular Carcinoma in the USA. Current Gastroenterology Reports. 2019;21:17. doi: 10.1007/s11894-019-0681-x. - DOI - PubMed
    1. Moawad AW, et al. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma. 2020;7:77–89. doi: 10.2147/JHC.S224471. - DOI - PMC - PubMed
    1. Pesapane F, Nezami N, Patella F, Geschwind J. New concepts in embolotherapy of HCC. Medical Oncology. 2017;34:58. doi: 10.1007/s12032-017-0917-2. - DOI - PubMed

MeSH terms